Cowen and Company reiterated their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a research report released on Tuesday morning. The brokerage currently has a $150.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the company. Vetr cut Celgene Corporation from a buy rating to a hold rating and set a $145.17 target price on the stock. in a research report on Wednesday, September 6th. BTIG Research reiterated a neutral rating on shares of Celgene Corporation in a research report on Tuesday, September 5th. Cantor Fitzgerald reiterated a buy rating on shares of Celgene Corporation in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $175.00 target price on shares of Celgene Corporation in a research report on Wednesday, August 9th. Finally, Cann restated a buy rating and issued a $175.00 price target on shares of Celgene Corporation in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. Celgene Corporation has an average rating of Buy and a consensus price target of $149.34.

Shares of Celgene Corporation (NASDAQ CELG) traded up 1.02% during mid-day trading on Tuesday, hitting $142.04. The stock had a trading volume of 5,983,997 shares. The firm has a market cap of $111.12 billion, a PE ratio of 43.99 and a beta of 1.89. The firm has a 50 day moving average price of $134.97 and a 200 day moving average price of $127.46. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.69.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the previous year, the firm earned $1.44 earnings per share. The business’s revenue was up 18.7% compared to the same quarter last year. Equities analysts predict that Celgene Corporation will post $7.33 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Celgene Corporation (CELG) Given “Buy” Rating at Cowen and Company” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/16/celgene-corporation-celg-given-buy-rating-at-cowen-and-company.html.

In related news, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 267,476 shares of company stock worth $35,812,841. 0.95% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Lincoln Capital Corp raised its holdings in Celgene Corporation by 0.6% in the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares during the last quarter. Neuberger Berman Group LLC raised its holdings in Celgene Corporation by 4.0% in the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares during the last quarter. Swiss National Bank raised its holdings in Celgene Corporation by 27.2% in the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after acquiring an additional 588,000 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Celgene Corporation by 9.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares during the last quarter. Finally, Boston Partners raised its holdings in Celgene Corporation by 0.3% in the 1st quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock valued at $24,620,000 after acquiring an additional 541 shares during the last quarter. Institutional investors own 79.43% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.